Wall Street analysts forecast that aTyr Pharma, Inc. (NASDAQ:LIFE) will post earnings of ($0.43) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for aTyr Pharma’s earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.48). aTyr Pharma reported earnings per share of ($0.53) during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.9%. The firm is scheduled to announce its next quarterly earnings results on Thursday, March 15th.

On average, analysts expect that aTyr Pharma will report full-year earnings of ($1.93) per share for the current financial year, with EPS estimates ranging from ($1.98) to ($1.88). For the next financial year, analysts expect that the firm will report earnings of ($1.78) per share, with EPS estimates ranging from ($2.05) to ($1.37). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover aTyr Pharma.

aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.07.

Several analysts have weighed in on the stock. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Saturday, November 18th. ValuEngine cut shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. aTyr Pharma presently has a consensus rating of “Hold” and a consensus price target of $4.81.

A number of institutional investors have recently modified their holdings of the business. Artal Group S.A. grew its stake in aTyr Pharma by 100.0% during the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 250,000 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of aTyr Pharma by 44.1% during the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 25,676 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of aTyr Pharma during the third quarter valued at approximately $455,000. 58.30% of the stock is currently owned by hedge funds and other institutional investors.

Shares of aTyr Pharma (NASDAQ LIFE) traded down $0.15 during trading on Friday, reaching $3.35. 20,881 shares of the company’s stock traded hands, compared to its average volume of 45,425. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.49 and a quick ratio of 9.49. The company has a market capitalization of $104.15, a PE ratio of -1.65 and a beta of 3.60. aTyr Pharma has a 1 year low of $2.30 and a 1 year high of $6.50.

WARNING: This article was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://theolympiareport.com/2018/02/10/0-43-earnings-per-share-expected-for-atyr-pharma-inc-life-this-quarter-2.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.